Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
275.08 USD | -0.04% |
|
-0.59% | +18.45% |
07-10 | Deutsche Bank Adjusts Price Target on CME Group to $273 From $266, Maintains Hold Rating | MT |
07-10 | Sector Update: Financial Stocks Decline Premarket Thursday | MT |
Highlights: CME Group Inc.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses: CME Group Inc.
- The company's earnings growth outlook lacks momentum and is a weakness.
- With a 2025 P/E ratio at 26.27 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings Chart: CME Group Inc.
Source: Surperformance
ESG chart: CME Group Inc.
Source: MSCI
Fundamentals (Composite) | Global Valuation (Composite) | Financial estimates revisions (Composite) | Capi.($) | ||
---|---|---|---|---|---|
99.13B | |||||
29.03B | |||||
11.38B | |||||
10.33B | |||||
9.04B | |||||
5.79B | |||||
4.78B | |||||
- | 3.85B | ||||
2.14B | |||||
Average | 19.5B | ||||
Weighted average by Cap. |
Investor (Composite)
Trader (Composite)
ESG MSCI
BBB
Financials
Revenue growth
EPS growth
Capital Efficiency (Composite)
Net Margin
Financial Health (Composite)
Valuation
P/E
EV/Revenue
EV/EBITDA
PBR
Dividend Yield
Revisions
Revenue revisions (1 year)
Revenue revisions (4 months)
Revenue revisions (1 month)
EPS revisions (1 year)
EPS revisions (4 months)
Consensus
Analysts' buy/sell recommendations
Analysts' recommendations evolution (4 months)
Analysts' target price
Analysts' target price evolution (4 months)
Analysts' target price evolution (1 year)
Business Predictability
Surprise rates
Analysts' coverage
Analysts' recommendations divergence
Analysts' Target price divergence
Financial estimates divergence
ESG
Environment
Social
Governance
Controversy
Ethical controversies
Human rights controversies
Tax subsidies controversies
Sharia compliant
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- CME Stock
- Ratings CME Group Inc.
Select your edition
All financial news and data tailored to specific country editions

MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition